Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab

Overview of attention for article published in Oncologist, July 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

facebook: 1 Facebook page

Readers on

mendeley: 11 Mendeley

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 35,772 followers.

少し考察。子宮体癌の試験（KEYNOTE-775/309）では患者背景として高齢欧米人で肥満患者が多いとのこと。くりにかる先生のご指摘通り，それによる影響はあるのだろう。 https://t.co/mYZ8E4ygou

📖Pembro+LENのAEマネジメント（子宮体癌）実症例から気付かされたが、この組み合わせはRCCも含めて、関節痛が明らかに多い。適正ガイドではあまり目立つような記載はされていない。 irAE関節炎とは異なり熱感、腫脹のない疼痛、という印象🦴 https://t.co/v9MslBXfOp

Learn how the successful management of #AEs enhances the potential of #lenvatinib + #pembrolizumab treatment for advanced #EC. Discover key strategies for maximizing benefits while minimizing treatment disruptions. 👉https://t.co/TrMfCN5zc9 #MedEd #o…

RT @OncJournal: This report reviewed AEs from combination #lenvatinib + #pembrolizumab in patients with advanced #endometrialcancer (Study-…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.